Navigation Links
UCLA researchers develop T-cells from human embryonic stem cells

Researchers from the UCLA AIDS Institute and the Institute for Stem Cell Biology and Medicine have demonstrated for the first time that human embryonic stem cells can be genetically manipulated and coaxed to develop into mature T-cells, raising hopes for a gene therapy to combat AIDS.

The study, to be published the week of July 3 in the online edition of the Proceedings of the National Academy of Sciences, found that it is possible to convert human embryonic stem cells into blood-forming stem cells that in turn can differentiate into the helper T-cells that HIV specifically targets. T-cells are one of the body's main defenses against disease.

The results mark the first time that scientists have been able to derive T-cells out of human embryonic stem cells, said Zoran Galic, assistant research biologist, and lead researcher on the study.

"This tells you that you may be able to use human embryonic stem cells to treat T cell and other blood diseases. This could be a very important weapon in the fight against AIDS," Galic said.

The study is available at http://www.pnas.org/papbyrecent.shtml.

In their study, the researchers cultured human embryonic stem cells, which were incubated on mouse bone marrow support cells, which in turn converted them into blood forming cells. Those cells were then injected into a human thymus gland that had been implanted in a mouse, and the thymus then changed those blood-forming cells into T-cells. Located just above the heart in humans, the thymus is the organ where T-cells develop. It gradually shrinks in adults, weakening the immune system over time.

These results indicate that it is possible to decipher the signals that control the development of embryonic stem cells into mature T-cells, said study co-author Jerome Zack, associate director of the UCLA AIDS Institute, and professor of medicine and of microbiology,
immunology and molecul ar genetics at the David Geffen School of Medicine at UCLA.

"That way we can eventually repopulate the immune system in patients needing T-cells," Zack said.

This in turn could give rise to gene therapy approaches to treat other diseases involving T-cells. In addition to HIV, for instance, the technique could be used to treat severe combined immunodeficiency, or the "bubble boy disease," which leaves its victims without a working immune system, forcing them to a life in an antiseptic, germ-free environment.


'"/>

Source:University of California - Los Angeles


Related biology news :

1. NYU researchers simulate molecular biological clock
2. Vital step in cellular migration described by UCSD medical researchers
3. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
4. UCSD researchers maintain stem cells without contaminated animal feeder layers
5. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
6. New protein discovered by Hebrew University researchers
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Agilent Technologies releases automated literature search tool for biology researchers
9. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
10. Yale researchers identify molecule for detecting parasitic infection in humans
11. US life expectancy about to decline, researchers say
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied ... that the global biometric technology market is expected to generate revenue of $10.72 billion ... Continue Reading ... Allied Market Research ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... Switzerland (PRWEB) , ... January ... ... provider of advanced software solutions for pharmaceutical research and development (R&D), today ... expertise in omic data analysis and interpretation for the rapidly evolving field ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , ... PIP) and Altimmune, Inc., a privately-held immunotherapeutics company ... a definitive agreement for the merger of PharmAthene ... investors include Novartis Venture Fund, HealthCap, Truffle Capital ... a fully-integrated and diversified immunotherapeutics company with four ...
(Date:1/19/2017)... Mass. , Jan. 19, 2017 AquaBounty ... focused on enhancing productivity in aquaculture and a majority-owned ... announces that it has completed the listing of its ... the equity subscription from Intrexon. "AquaBounty,s listing ... that will broaden our exposure to the U.S. markets ...
Breaking Biology Technology: